The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts

Priya Muthu, Katarzyna Kazmierczak, Michelle Jones, Danuta Szczesna-Cordary

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Phosphorylation of the myosin regulatory light chain (RLC) by Ca2+-calmodulin-activated myosin light chain kinase (MLCK) is known to be essential for the inotropic function of the heart. In this study, we have examined the effects of MLCK-phosphorylation of transgenic (Tg) mouse cardiac muscle preparations expressing the D166V (aspartic acid to valine)-RLC mutation, identified to cause familial hypertrophic cardiomyopathy with malignant outcomes. Our previous work with Tg-D166V mice demonstrated a large increase in the Ca2+ sensitivity of contraction, reduced maximal ATPase and force and a decreased level of endogenous RLC phosphorylation. Based on studies demonstrating the beneficial and/or protective effects of cardiac myosin phosphorylation for heart function, we hypothesized that an ex vivo phosphorylation of Tg-D166V cardiac muscle may rescue the detrimental contractile phenotypes observed earlier at the level of single myosin molecules and in Tg-D166V papillary muscle fibres. We showed that MLCK-induced phosphorylation of Tg-D166V cardiac myofibrils and muscle fibres was able to increase the reduced myofibrillar ATPase and reverse an abnormally increased Ca2+ sensitivity of force to the level observed for Tg-wild-type (WT) muscle. However, in contrast to Tg-WT, which displayed a phosphorylationinduced increase in steady-state force, the maximal tension in Tg-D166V papillary muscle fibres decreased upon phosphorylation. With the exception of force generation data, our results support the notion that RLC phosphorylation works as a rescue mechanism alleviating detrimental functional effects of a disease causing mutation. Further studies are necessary to elucidate the mechanism of this unexpected phosphorylation-induced decrease in maximal tension in Tg-D166V-skinned muscle fibres.

Original languageEnglish
Pages (from-to)911-919
Number of pages9
JournalJournal of Cellular and Molecular Medicine
Volume16
Issue number4
DOIs
StatePublished - Dec 1 2012

Fingerprint

Myosin Light Chains
Phosphorylation
Myosin-Light-Chain Kinase
Myocardium
Papillary Muscles
Light
Transgenic Mice
Adenosine Triphosphatases
Familial Hypertrophic Cardiomyopathy
Cardiac Myosins
Muscles
Mutation
Myofibrils
Valine
Calmodulin
Myosins
Aspartic Acid
Phenotype

Keywords

  • Cardiac hypertrophy
  • Muscle fibres
  • Mutation
  • Myosin light chain kinase
  • Myosin regulatory light chain
  • Phosphorylation
  • Transgenic mice

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts. / Muthu, Priya; Kazmierczak, Katarzyna; Jones, Michelle; Szczesna-Cordary, Danuta.

In: Journal of Cellular and Molecular Medicine, Vol. 16, No. 4, 01.12.2012, p. 911-919.

Research output: Contribution to journalArticle

Muthu, Priya ; Kazmierczak, Katarzyna ; Jones, Michelle ; Szczesna-Cordary, Danuta. / The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts. In: Journal of Cellular and Molecular Medicine. 2012 ; Vol. 16, No. 4. pp. 911-919.
@article{27f7b544b5dc49daaaa7903b18c739c8,
title = "The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts",
abstract = "Phosphorylation of the myosin regulatory light chain (RLC) by Ca2+-calmodulin-activated myosin light chain kinase (MLCK) is known to be essential for the inotropic function of the heart. In this study, we have examined the effects of MLCK-phosphorylation of transgenic (Tg) mouse cardiac muscle preparations expressing the D166V (aspartic acid to valine)-RLC mutation, identified to cause familial hypertrophic cardiomyopathy with malignant outcomes. Our previous work with Tg-D166V mice demonstrated a large increase in the Ca2+ sensitivity of contraction, reduced maximal ATPase and force and a decreased level of endogenous RLC phosphorylation. Based on studies demonstrating the beneficial and/or protective effects of cardiac myosin phosphorylation for heart function, we hypothesized that an ex vivo phosphorylation of Tg-D166V cardiac muscle may rescue the detrimental contractile phenotypes observed earlier at the level of single myosin molecules and in Tg-D166V papillary muscle fibres. We showed that MLCK-induced phosphorylation of Tg-D166V cardiac myofibrils and muscle fibres was able to increase the reduced myofibrillar ATPase and reverse an abnormally increased Ca2+ sensitivity of force to the level observed for Tg-wild-type (WT) muscle. However, in contrast to Tg-WT, which displayed a phosphorylationinduced increase in steady-state force, the maximal tension in Tg-D166V papillary muscle fibres decreased upon phosphorylation. With the exception of force generation data, our results support the notion that RLC phosphorylation works as a rescue mechanism alleviating detrimental functional effects of a disease causing mutation. Further studies are necessary to elucidate the mechanism of this unexpected phosphorylation-induced decrease in maximal tension in Tg-D166V-skinned muscle fibres.",
keywords = "Cardiac hypertrophy, Muscle fibres, Mutation, Myosin light chain kinase, Myosin regulatory light chain, Phosphorylation, Transgenic mice",
author = "Priya Muthu and Katarzyna Kazmierczak and Michelle Jones and Danuta Szczesna-Cordary",
year = "2012",
month = "12",
day = "1",
doi = "10.1111/j.1582-4934.2011.01371.x",
language = "English",
volume = "16",
pages = "911--919",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts

AU - Muthu, Priya

AU - Kazmierczak, Katarzyna

AU - Jones, Michelle

AU - Szczesna-Cordary, Danuta

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Phosphorylation of the myosin regulatory light chain (RLC) by Ca2+-calmodulin-activated myosin light chain kinase (MLCK) is known to be essential for the inotropic function of the heart. In this study, we have examined the effects of MLCK-phosphorylation of transgenic (Tg) mouse cardiac muscle preparations expressing the D166V (aspartic acid to valine)-RLC mutation, identified to cause familial hypertrophic cardiomyopathy with malignant outcomes. Our previous work with Tg-D166V mice demonstrated a large increase in the Ca2+ sensitivity of contraction, reduced maximal ATPase and force and a decreased level of endogenous RLC phosphorylation. Based on studies demonstrating the beneficial and/or protective effects of cardiac myosin phosphorylation for heart function, we hypothesized that an ex vivo phosphorylation of Tg-D166V cardiac muscle may rescue the detrimental contractile phenotypes observed earlier at the level of single myosin molecules and in Tg-D166V papillary muscle fibres. We showed that MLCK-induced phosphorylation of Tg-D166V cardiac myofibrils and muscle fibres was able to increase the reduced myofibrillar ATPase and reverse an abnormally increased Ca2+ sensitivity of force to the level observed for Tg-wild-type (WT) muscle. However, in contrast to Tg-WT, which displayed a phosphorylationinduced increase in steady-state force, the maximal tension in Tg-D166V papillary muscle fibres decreased upon phosphorylation. With the exception of force generation data, our results support the notion that RLC phosphorylation works as a rescue mechanism alleviating detrimental functional effects of a disease causing mutation. Further studies are necessary to elucidate the mechanism of this unexpected phosphorylation-induced decrease in maximal tension in Tg-D166V-skinned muscle fibres.

AB - Phosphorylation of the myosin regulatory light chain (RLC) by Ca2+-calmodulin-activated myosin light chain kinase (MLCK) is known to be essential for the inotropic function of the heart. In this study, we have examined the effects of MLCK-phosphorylation of transgenic (Tg) mouse cardiac muscle preparations expressing the D166V (aspartic acid to valine)-RLC mutation, identified to cause familial hypertrophic cardiomyopathy with malignant outcomes. Our previous work with Tg-D166V mice demonstrated a large increase in the Ca2+ sensitivity of contraction, reduced maximal ATPase and force and a decreased level of endogenous RLC phosphorylation. Based on studies demonstrating the beneficial and/or protective effects of cardiac myosin phosphorylation for heart function, we hypothesized that an ex vivo phosphorylation of Tg-D166V cardiac muscle may rescue the detrimental contractile phenotypes observed earlier at the level of single myosin molecules and in Tg-D166V papillary muscle fibres. We showed that MLCK-induced phosphorylation of Tg-D166V cardiac myofibrils and muscle fibres was able to increase the reduced myofibrillar ATPase and reverse an abnormally increased Ca2+ sensitivity of force to the level observed for Tg-wild-type (WT) muscle. However, in contrast to Tg-WT, which displayed a phosphorylationinduced increase in steady-state force, the maximal tension in Tg-D166V papillary muscle fibres decreased upon phosphorylation. With the exception of force generation data, our results support the notion that RLC phosphorylation works as a rescue mechanism alleviating detrimental functional effects of a disease causing mutation. Further studies are necessary to elucidate the mechanism of this unexpected phosphorylation-induced decrease in maximal tension in Tg-D166V-skinned muscle fibres.

KW - Cardiac hypertrophy

KW - Muscle fibres

KW - Mutation

KW - Myosin light chain kinase

KW - Myosin regulatory light chain

KW - Phosphorylation

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=84863058123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863058123&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2011.01371.x

DO - 10.1111/j.1582-4934.2011.01371.x

M3 - Article

C2 - 21696541

AN - SCOPUS:84863058123

VL - 16

SP - 911

EP - 919

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 4

ER -